Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid organ transplant recipient.~* Age ≥18 years~* VZV-seronegative at time of transplant~* ≥90 days post-transplant~* Able to provide informed consent~Exclusion Criteria:~* Has already received the recombinant subunit Herpes zoster vaccine in the past~* Ongoing CMV viremia \> 200 IU/mL~* HIV infection~* Diagnosis of malignancy (e.g. PTLD)~* History of a severe allergic reaction (anaphylactic reaction) after any vaccine~* Documented Chickenpox or Shingles after transplantation~* Congenital immunodeficiency (e.g., CVID)~* Treatment for rejection in the past 30 days~* Immunoglobulin in the past 30 days or anticipated to receive immunoglobulin~* Anti-CD20 monoclonal antibody in the past 6 months or anticipated to receive Anti-CD20 monoclonal antibody~* Plasmapheresis in the past 30 days or anticipated to receive plasmapheresis~* Febrile illness in the past one week~* Unable to comply with the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VZV seronegative Transplant Patients (Type: EXPERIMENTAL): recombinant subunit Herpes zoster vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).